Disabled Sports Eastern Sierra to Host Another Wounded Warrior Operation Mountain Freedom
Learn how this yearly therapeutic winter event has inspired the launch of their loftiest veteran program yet.
From January 28 to February 1, Disabled Sports Eastern Sierra (DSES) will hold their 13th Annual Operation Mountain Freedom program--a week long sport camp for active duty and veterans with disabilities.
This inspiring event hosted in beautiful Mammoth Lakes, California, encourages warriors with disabilities to face their challenges and fears through sports such as alpine skiing, snowboarding, and cross-country skiing as well as by attending social gatherings and listening to guest speakers.
Each year has seen the demand for this once-in-a-lifetime experience grow, ultimately inspiring DSES to address an expanded vision —the creation of the National Wounded Warrior Center—a facility solely dedicated to the mental and physical recovery of wounded warriors, to be built in Mammoth Lake, California.
To join the DSES fundraising initiative, go to www.WoundedWarriorsMammoth.org/Donate.
“Each year we see overwhelming interest in Operation Mountain Freedom, and are always saddened to have to place veterans on the waiting list,” explained Founder and Executive Director of Disabled Sports Eastern Sierra, Kathy Copeland. “This outcry for these programs is what convinced us it was time to go one step further.” The transformation we see in their lives is inspiring and we can do so much more.
Their goal is to build the first National Wounded Warrior Center, where they will be able to treat an estimated 300 veterans annually with adaptive sports training, physical therapy, counseling, continued education with an onsite community college, and post-treatment housing guidance.
“We have seen such a positive impact with Operation Mountain Freed
om,” said Executive Director Copeland. “In just a week's time you can already witness their growing confidence in their bodies and how this affects their ability to communicate and meet social challenges. Just think what could happen with more resources and time!”
DSES has launched a campaign to raise $12M of the needed $17.9M construction costs by mid-2019, so they can break ground by the end of the year.
To learn about donation opportunities, recurring giving plans, establishing a legacy, and in-kind contributions of services and construction materials please call the Disabled Sports Eastern Sierra office at 760-934-0791 or email Info@DisabledSportsEasternSierra.org.
National Wounded Warrior Center donations are accepted at: www.WoundedWarriorsMammoth.org/Donate.
About
Disabled Sports Eastern Sierra, is a nationally recognized adaptive sports program for children and adults with cognitive and physical disabilities, non-profit organization. Based in Mammoth Lakes, CA, DSES creates inspiring challenges, provides expert instruction, and rallies the community to comfortably accommodate people with disabilities.
The DSES Wounded Warrior Programs began in 2007 with a collaboration with Camp Pendleton and Balboa Naval Medical Hospital’s Marine Corps Wounded Warrior Battalion West. Wounded veterans from across the country now attend DSES Wounded Warrior programs, and participation has increased monumentally.
The success from the DSES Wounded Warrior programs is the true inspiration behind the creation of National Wounded Warrior Center. Donations accepted at: www.WoundedWarriorMammoth.org/Donate.
“You can’t put a price tag on an opportunity to come to a place as soothing as Mammoth for these Wounded Warriors –to feel like they’re not alone, that they’re not forgotten. It’s one thing for the government to do it, but it’s when private citizens and communities are doing it for the love of their fellow man that really touches the soldiers. It’s a chance to fundamentally save or change a person for the rest of their life.” -- Larry D. Nicholson, Ret. Commanding General, 1st Marine Division
Follow @DisabledSportsEasternSierra and @NationalWoundedWarriorCenter on Facebook for behind-the-scene snapshots, upcoming events, advocacy alerts, and campaign announcements.
Epidemics, Fear and Denial: How Every American Is Threatened
by: Jane M. Orient, M.D.
This is the one hundredth anniversary of the great influenza pandemic of 1918. In his book The Great Influenza, John M. Barry described it as the deadliest plague in history. It killed more people in a year than the Black Death of the Middle Ages killed in a century.
The lack of a vaccine did not cause the flu. All epidemics start with an index case—which may or may not be identified. The great influenza may have begun in a patient in Kansas. The significance of the case was reportedly recognized by a country doctor, who was ignored. As the nation mobilized for World War I, and draftees from across the country were thrown together, illness spread and became much more virulent. Transport ships became “floating caskets.” Troop trains were “rolling coffins.” But Woodrow Wilson denied the existence or severity of the epidemic, and effective public health efforts were thwarted.
Despite this history, and the expenditure of billions of dollars, the U.S. is not much better prepared than in 1918. There have been warnings, such as Ebola, severe acute respiratory distress syndrome (SARS), novel H1N1 flu, and the 2014 outbreak of enterovirus D68 in schoolchildren. But when the threats recede, the nation goes back to sleep.
When different populations are thrown together, as in boot camp or college dorms when new freshmen arrive, there is a lot of sickness. Each group has a different pattern of colonizing microorganisms to which its members have immunity and others do not. There are terrible historical examples of native populations in the New World being devastated by diseases of European settlers.
Epidemics can happen naturally or through neglect—or they could be caused deliberately. Biological warfare is probably the very worst weapon of mass destruction.
One scenario is to embed a suicide agent incubating a deadly disease in a mass of migrants. Or there are doubtlessly innocent persons infected with deadly diseases to which Americans have no immunity among thousands of migrants overwhelming our border—from Central America and many other places.
The mainstream press and even part of mainstream medicine promotes denial. For example, an NBC News article quotes Dr. Paul Spiegel, who directs the Center for Humanitarian Health at Johns Hopkins School of Public Health: “There is no evidence to show that migrants are spreading disease.” The danger of introducing disease is “a false argument used to keep migrants out.” The article even quotes a study that purportedly shows that hepatitis, tuberculosis and HIV “generally only spread within the affected immigrant communities and not to the wider population.” Perhaps there is an invisible shield between an infected migrant and an American but not between him and someone newly arriving from his country?
Is this denialism?
No, that term is for those who don’t believe that we can change the climate and save the Planet by cutting off energy from the fuels that power 80 percent of the world’s economy. The supposed mainstream of media and organized medicine insists that “climate change”—catastrophic and human-caused—is the existential public health threat that eclipses all others. Let’s have uncontrolled migration, but tight global control of essential fuels.
Is concern about the caravan just “fearmongering”?
We don’t hear that term applied to those who say we must treat a child missing some mandated vaccines as a “Typhoid Mary” and bar him from schools or doctor’s offices—even though nobody ever caught a disease from a child that wasn’t infected with it. Rather, that’s the word for those who warn about tropical diseases, even if they are much more common and deadly than indigenous measles. Or for those concerned about tattooed MS-13 gang members, rapists, jihadists, human traffickers, and other criminals intent on harming Americans. Such people also infect, molest, assault, or murder people in their own countries and in the caravan.
Our nation faces real threats that produce genuine body counts from violence and disease. Instead, we are supposed to worry about carbon dioxide, invisible dust particles, and imperceptible phobias and isms. Not just worry, but shut down industries and shut out dissenters from public discourse.
A wall is indeed proposed—to confine the half of America that votes the “wrong” way and wants to protect American lives, liberties, and property.
We need an outbreak of common sense.
###
Jane M. Orient, M.D. obtained her undergraduate degrees in chemistry and mathematics from the University of Arizona in Tucson, and her M.D. from Columbia University College of Physicians and Surgeons in 1974. She completed an internal medicine residency at Parkland Memorial Hospital and University of Arizona Affiliated Hospitals and then became an Instructor at the University of Arizona College of Medicine and a staff physician at the Tucson Veterans Administration Hospital. She has been in solo private practice since 1981 and has served as Executive Director of the Association of American Physicians and Surgeons (AAPS) since 1989. She is currently president of Doctors for Disaster Preparedness. Since 1988, she has been chairman of the Public Health Committee of the Pima County (Arizona) Medical Society. She is the author of YOUR Doctor Is Not In: Healthy Skepticism about National Healthcare, and the second through fourth editions of Sapira's Art and Science of Bedside Diagnosis published by Lippincott, Williams & Wilkins. She authored books for schoolchildren, Professor Klugimkopf’s Old-Fashioned English Grammar and Professor Klugimkopf’s Spelling Method, published by Robinson Books, and coauthored two novels published as Kindle books, Neomorts and Moonshine. More than 100 of her papers have been published in the scientific and popular literature on a variety of subjects including risk assessment, natural and technological hazards and nonhazards, and medical economics and ethics. She is the editor of AAPS News, the Doctors for Disaster Preparedness Newsletter, and Civil Defense Perspectives, and is the managing editor of the Journal of American Physicians and Surgeons.
Texas A&M first in nation to train all health sciences students on opioid overdose reversal
BRYAN, Texas — With 91 Americans dying each day from opioid overdose, the Texas A&M University Health Science Centeris responding, advancing training and education in pain management and substance abuse in innovative ways. Texas A&M is the first health science center in the nation to commit to train every health professions student to administer a reversal agent to opioid overdose victims, and save lives.
Through the intensive 90-minute Opioid Overdose Education and Naloxone Administration (OENA) program, the institution will train every Texas A&M Health Science Center student across the state—totaling more than 5,000 students from the colleges of dentistry, medicine, nursing, pharmacy and public health—to recognize an opioid overdose and administer naloxone, a drug that can be administered as a nasal spray or injection to reverse the deadly effects of opioid overdoses.
The reversal agent is available as prescription medication, and some states, including Texas, allow naloxone to be distributed by pharmacists to the public without a prescription from a physician via a standing order. Texas also passed legislation allowing for community distribution of naloxone rescue kits by trained individuals to the general public in response to the rising crisis.Anyone is allowed to possess naloxone without a prescription, and use it in good faith to save the life of a person believed to be suffering from an opioid overdose.
“Naloxone is a life-saving treatment to help until emergency personnel arrive,” said Joy Alonzo, M. Engineering, PharmD, clinical assistant professor at the Texas A&M College of Pharmacy, who is leading the naloxone training effort at the Health Science Center. “The goal is to train our students how to administer naloxone and also educate them about the health care needs of the opioid crisis and spread that awareness to others.”
Alonzo is a member of the institution’s Opioid Task Force, which was formed in 2018 to reduce burdens from the opioid epidemic through collaborative action in research, education and community outreach, across the health sciences. Training of all health professions students is an important component of both the education and community outreach initiatives of the task force.
“Whenever you’re faced with a crisis, you need creative solutions,” said Carrie L. Byington, MD, vice chancellor for health services at The Texas A&M University System, senior vice president of the Texas A&M Health Science Center and dean of the Texas A&M College of Medicine. “The best ideas come when multiple viewpoints are at the table, and that’s the idea behind our interprofessional Opioid Task Force. Together, we’re reducing the stigma associated with opioids, and empowering the next generation of health care professionals to become advocates for naloxone administration within their own communities, wherever they may practice after graduation.”
Students are already putting what they’ve learned to practice. Pharmacy students, who were trained early on through Operation Naloxone, are now actively training first responders and members of the community in how to recognize an overdose and administer naloxone.
“We have seen five reversals from trainings provided to communities,” Alonzo said. “We’re preventing overdose deaths in our communities, and providing opportunities for people with opioid use disorder to access treatment and recovery—saving lives.”
The task force’s efforts also translate well beyond Texas’ borders. Task Force representatives, including Byington and Alonzo, are engaged at the national level, with the American Medical Association Alliance and the Association of American Medical Colleges.
There’s also an evaluation component planned. “We’re going to survey the students on the effectiveness of the training, and then we're going to re-survey them every 12 months until they graduate to see what sticks and how their attitudes about opioid use disorder changes,” Alonzo said. “We need to change the perspective of the next generation of health care providers, and this initiative is one component of that.”
The ultimate goal is to destigmatize substance use disorders and teach providers—and society in general—to consider it a chronic health condition, not a lack of willpower or a character flaw. Naloxone doesn’t solve the problem or help people overcome addiction, but it does save their lives so they have the opportunity to seek treatment.
“This sort of training should be very common, just like people are trained in CPR,” Alonzo said. “You may never need it, but if the situation does arise, you need to know how to do it right and feel confident that you can save a life.”
###
About Texas A&M University Health Science Center
Texas A&M University Health Science Center is transforming healththrough innovative research, education and service in dentistry, medicine, nursing, pharmacy, public health and medical sciences. As an independent state agency and academic unit of Texas A&M University, the health science center serves the state through campuses in Bryan-College Station, Dallas, Temple, Houston, Round Rock, Kingsville, Corpus Christi and McAllen. Learn more at vitalrecord.tamhsc.edu or follow @TAMHSC on Twitter.
Trusted Cold and Flu Brand BENYLIN® Launches NEW Lozenge Product
J&J and JWT Canada dramatize long-lasting relief in "Work Day"
TORONTO, Dec. 10, 2018 /CNW/ - It's no secret Canada – winter is coming. And what's more predictable than the cold weather? Cold and flu season. Fortunately, the experts in cough control BENYLIN® have got us covered. Earlier this fall, Johnson & Johnson Canada and J. Walter Thompson Canada released a brand-new campaign to globally launch the new BENYLIN® Sore Throat Lozenge product.
With over 25 different cold and flu products, BENYLIN® specializes in cough and cold control. The BENYLIN® Sore Throat Lozenge product is brand-new and has been uniquely formulated with a dual layer that works in two ways. First, the outer layer with cooling flavour agents quickly dissolves, providing an immediate cooling sensation to soothe your throat. Then, the inner core, containing an anesthetic, provides targeted relief of your sore throat pain for up to two hours. While there are other lozenges products that contain medicinal ingredients, the BENYLIN® difference is the two-hour duration of long-lasting relief that the product provides.
"Lozenges are the lightweights of the cough and cold category – generally consumers don't expect much of them. Consumers look to them to soothe and relieve their sore throat while they're sucking on them but not after they've dissolved. BENYLIN® lozenges last for 2 hours so it was important to ensure that message was clear," said Ishita Saha, Market Unit Director, Pain Care and CCFS, Johnson & Johnson. To convince the consumer that BENYLIN® Sore Throat Lozenges are different and truly long-lasting, J. Walter Thompson Canada decided to take a light-hearted approach that would resonate with the consumer. "Some of my favourite ads from the past and some of the most convincing have been straightforward demonstrations," said Cory Eisentraut, Executive Creative Director, J. Walter Thompson Canada. "With this launch, we wanted to find a simple way to demonstrate the two-hour relief but do it in a fun, memorable way."
To further demonstrate the length of relief the BENYLIN® lozenges provide, the teams worked together to strategically develop a media plan that would place the ad in contextual environments. First on the list: movie theatres. This placement is particularly clever for two reasons: firstly, the two-hour relief message correlates to the typical length of a film in the cinema and secondly, no one wants to be that person coughing throughout the entire show.
The BENYLIN® Sore Throat Lozenge product is now available in store. Check out the supporting TV and digital campaign "Work Day" here: https://www.youtube.com/watch?v=8JF-g_GImoU
ABOUT JOHNSON & JOHNSON:
In Canada, Johnson & Johnson Inc., the consumer health company has offices in Markham and Montreal. They market and sell some of Canada's leading brands in the Baby Care, Oral Health Care, Wound Care, Nicotine Replacement Therapy, Skin and Hair Care, Nutritionals, Non-Prescription Drugs and Eye Care categories. At Johnson & Johnson Inc., the mission is to enrich the health and wellness of every Canadian, every day. Behind every one of the brands is a tradition of innovative research, cutting-edge technology, and a deep commitment to delighting consumers with products that they can trust for their entire family.
ABOUT J. WALTER THOMPSON WORLDWIDE:
J. Walter Thompson Worldwide, the world's best-known marketing communications brand, has been making pioneering solutions that build enduring brands and business for more than 150 years. Headquartered in New York, J. Walter Thompson is a true global network with more than 200 offices in over 90 countries, employing nearly 10,000 marketing professionals. The agency consistently ranks among the top networks in the world and continues to have a dominant presence in the industry by staying on the leading edge – from hiring the industry's first female copywriter to developing award-winning branded content today. For more information, please visit www.jwt.com and follow us @JWT_Worldwide.
SOURCE J. Walter Thompson Canada
Adaptiiv announces major release
HALIFAX, Dec. 10, 2018 /CNW/ - Adaptiiv Medical Technologies Inc. (Adaptiiv), an innovative medical technology company, announced today the release of its most significant advancement to date of its medical software, 3D Bolus 2.0. This release includes numerous updates to existing features based on client feedback, as well as new features such as;
- Hot Spot Correction - Improved hotspot correction algorithm allowing for automatic reduction of hotspots (contoured in the TPS) by a user-selected amount.
- Cleaving - Custom cleaving feature provides ability to easily cleave a bolus or applicator into two parts, at any angle.
- HDR Surface Brachytherapy - Enhanced algorithm that improves the way catheter trajectories are generated. In addition, the module now notifies Users of curvatures that may be of concern and provides the ability to fix these potential problem areas.
- In Vivo Dosimetry - Automatically create and print dosimeter pockets directly within the Bolus/Applicator. Appropriate caps which will fill the pockets when dosimeters are not in use, are also printed.
"This is an exciting time for our organization," said Adaptiiv CTO, Alex Dunphy. "Adaptiiv is the first company in the world to receive FDA 510k clearance for 3D printing software used in radiation oncology. Version 2.0 of the 3D Bolus Software was built by gathering and analyzing feedback from our customers in order to develop a product that meets day-to-day clinical needs. 3D Bolus 2.0 enables our customers to improve the standard of care they provide to the patients, through the 3D printing of patient-specific accessories."
About Adaptiiv
Adaptiiv Medical Technologies Inc. (formerly 3D Bolus Inc.) is the definitive 3D technology platform for radiation oncology. Headquartered in Halifax, Nova Scotia, Canada, Adaptiiv is shaping the future of patient-specific healthcare through innovation and collaboration with leading Cancer Centres throughout the world. Adaptiiv has 510(k) clearance, is ISO 13485 certified and has received CE Mark.
Website: http://www.adaptiiv.com/
SOURCE Adaptiiv Medical Technologies Inc.
Access to Digital Health Services Transforming Physicians' Approach to Patient Care in Canada
TORONTO, Dec. 10, 2018 /CNW/ - Physician access to connected health information in Canada is now high, yet Canadians' access to virtual care services is limited, according to a new study conducted by Canada Health Infoway (Infoway).
The 2018 Canadian Physician Survey (2018 CPS) is the first national survey of physicians exclusively focused on the use of digital health technologies in practice. It was developed and conducted in collaboration with national physician associations, the Canadian Institute for Health Information (CIHI) and the Canadian Medical Directory (Scotts Directories).
Close to 1,400 practising physicians completed the survey, which covers topics such as electronic medical record (EMR) adoption and use, access to connected health information and patient access to virtual care services.
According to the 2018 CPS, four per cent of primary care physicians and nine per cent of specialists say that patients in their practice can visit with them online via a face-to-face virtual visit — a digital service that interests more than 40 per cent of Canadians, according to another recent Infoway survey.
The 2018 CPS also found that:
- 84 per cent of primary care physicians and 89 per cent of specialists report that they have access to connected health information from care settings outside their main practice.
- 82 per cent of primary care physicians and 77 per cent of specialists say they provide more efficient care with electronic records.
- 31 per cent of primary care physicians report optimized EMR use.
- 38 per cent of primary care physicians and 47 per cent of specialist physicians currently offer patients at least one virtual care or e-service. This is mainly driven by practices/clinics becoming more accessible to patients via email communication (24 per cent of primary care and 40 per cent of specialist practices/clinics), but the majority of physicians do not spend any time during their day electronically communicating with patients.
"Canadians continue to tell us that they want access to digitally-enabled health services, including the ability to email their doctors and book appointments online," said Michael Green, President & CEO, Infoway. "Canadians deserve modern, 21st century health services, and our goal is to provide them with access to digital services that will improve their care experiences and health outcomes."
Download the 2018 Canadian Physician Survey.
About Canada Health Infoway
Canada Health Infoway helps to improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada. Through our investments, we help deliver better quality and access to care and more efficient delivery of health services for patients and clinicians. Infoway is an independent, not-for-profit organization funded by the federal government.
Media inquiries:
Karen Schmidt
Director, Corporate Communications
Canada Health Infoway
Tel: (416) 595-3167
Email Us
Follow @Infoway
SOURCE Canada Health Infoway
Legal cannabis industry’s crypto tax breakthrough
Cannabis retailers empowered to adhere to tax laws thanks to new payments platform partnership
New York, December 10, 2018 - The legal US cannabis retail industry took another step towards mainstream business compliance today – as cannabis retailers became empowered to track all transactional data related to taxes, gains and losses.
Cryptocurrencies have proved a popular form of payment at cannabis shops in the 33 US states where sales are now legal – but crypto tax laws remain vague, and it has proved difficult for retailers to produce accurate and compliant accounts.
But the process has become far more simple and straightforward, thanks to the integration of
NODE40’s pioneering cryptocurrency accounting and tax platform into
Alt Thirty Six – the blockchain payments platform designed for the cannabis industry.
The partnership enables retailers to stay tax compliant and within the law, while the IRS will be helped to receive the taxes it is due from an exponentially expanding industry.
Announcing the partnership today, Perry Woodin, Chief Executive Officer of NODE40, said: “With the many cryptocurrency transactions Alt Thirty Six facilitates, our solution will make it simple for them to maintain accurate reporting and sound compliance. With this partnership, NODE40’s Balance platform is expanding its reach to serve enterprise clients, in addition to individual cryptocurrency holders.”
Alt Thirty Six uses Dash digital currency as an alternative to cash, making payments faster, more secure and less expensive to both the merchant and the consumer.
NODE40’s Balance platform will help customers receive and process transactional data related to Dash payments, track sales tax and income valuations, verify blockchain transactions and report cryptocurrency gains and losses, and deliver summary-level information from processed data.
Alt Thirty Six CEO and Co-Founder Ken Ramirez said: “NODE40 values top-notch technology, and it’s clear that their leadership team understands our mission to take the growing cannabis industry completely cashless.”
“We believe that digital payments are the future of global commerce, and we are confident that the combination of blockchain technology and Dash digital currency will revolutionize the payments industry."
Balance is a Software-as-a-Service (Saas) platform that offers both enterprise and individual cryptocurrency users the ability to generate fiat denominated ledgers by analyzing the blockchain to identify capital gains and losses.
Users can upload data from various hardware or software wallets, as well as exchanges like Coinbase, GDAX, Gemini and Bittrex. When a user authorizes read access to their transaction history, Balance provides both a high level and detailed summary, including date, time, transaction type, short-term or long-term gains, and price differential.
Once the gains and losses are calculated, the service automatically details the information on a worksheet that can be shared with a CPA to file at tax time. For on-blockchain transactions, Balance uses specific identification, the only methodology in-line with IRS guidance and AICPA recommendations.
About NODE40
NODE40 is a financial services provider for individuals and businesses that have interacted with cryptocurrency. NODE40’s flagship product, Balance, is a robust cryptocurrency tax calculation software that integrates directly with major cryptocurrency exchanges and custodial wallets. Members of the blockchain community transacting in, trading, or mining digital currency, have triggered taxable events and may be unaware of how to properly disclose these transactions to the government. For more information, visit
https://www.node40.com/balance/
About Alt Thirty Six
Alt Thirty Six believes simplicity is the ultimate form of sophistication. their fully-integrated digital payments solution solves all the problems associated with Bitcoin, traditional payments, and banking solutions. As companies struggle to minimize the cost of accepting payments, they completely eliminate the fees charged by processors and banks. They see the potential for digital currency to revolutionize financial services, making commerce faster, more secure, and less expensive. For more information, visit
www.altthirtysix.comTissue Regeneration Therapeutics and RoosterBio Inc. Form Strategic Alliance to Commercialize Umbilical Cord Tissue Cell Technology
TORONTO, Dec. 10, 2018 /CNW/ - Today Tissue Regeneration Therapeutics Inc. (TRT) and RoosterBio Inc. (RBI) announce an important strategic alliance to advance their shared goal of accelerating the development of the Regenerative Medicine and Cellular Therapy fields. This collaboration will be focused on applying RoosterBio's unique scale-up bioprocess systems to TRT's core technology around human umbilical cord perivascular cells (HUCPVCs). Together, it is anticipated that these technology platforms will establish a new level of perivascular stromal/stem cell manufacturing productivity, thus creating newfound efficiencies in Regenerative Medicine.
"RoosterBio have established themselves as leaders in hMSC bioprocess systems, and we are enthusiastic to apply their scalable, cGMP production platforms to our patented umbilical cord perivascular cellular (TXP) technology. We believe that our TXP technology has unique advantages over other mesenchymal cell sources, and leveraging RoosterBio's scalable manufacturing platforms will accelerate our therapeutic programs. Overall, this strategic alliance will have far reaching implications in the fields of Regenerative Medicine and Cellular Therapy." said John E. Davies, DSc, President & CEO of TRT.
Margot Connor, RoosterBio's CEO states "Tissue Regeneration Therapeutics have established themselves as leaders in cord tissue perivascular cells, and we are excited to collaborate to help drive cell manufacturing productivity within their unique technology platform." She adds, "We've experienced great collaboration with TRT over the last few years, and we look forward to deepening our relationship with them."
About Tissue Regeneration Therapeutics Inc.:
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) technology platforms that include culture expanded cells (TXP) and engineered cells (eTXP). The latter are designed for specific unmet needs, in addition to the constitutive advantages of TXP, by the engineered secretion of cytokines, growth factors or monoclonal antibodies for targeted therapies. TRT is the first company in the world to have issued and allowed patents in the USA, Europe and Australasia, for extraction of these unique cells from umbilical cord tissue, and their gene engineering. Additional information is available at http://www.verypowerfulbiology.com
About RoosterBio, Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high volume, affordable, and well-characterized adult hMSCs paired with highly engineered bioprocess media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog "Democratizing Cell Technologies" (www.roosterbio.blogspot.com).
SOURCE Tissue Regeneration Therapeutics Inc.
WHAT ARE PHTHALATES?
How Can These Culprits in Plastics Contribute to Weight Gain?
By Eddie Fatakhov M.D. (a.k.a. Dr. Fat-Off)
Phthalates, not to be confused with Pilates exercises, are semi volatile organic compounds found in plastics because they make them soft and flexible.
Though commercially useful, these chemicals can easily leach out of plastics to contaminate our food, water supply, and even the air we breathe. This is when phthalates become a real problem
How do phthalates cause problems?
Phthalates are also endocrine disruptors. Your endocrine system is made up a network of glands (thyroid gland, ovaries, etc.) and the hormones (insulin, estrogen, etc.) they produce. These hormones are used to communicate with cells and tissues to regulate many functions – this can result in insulin resistance, obesity and thyroid disease.
Phthalates, once in the body, disrupt the endocrine system in the following negative ways:
- They mimic, or partly mimic, our naturally occurring hormones
- When they mimic they bind to our hormone receptors so that our naturally occurring hormones can’t
- This bonding causes our bodies to have irregular physical responses since the hormones that are supposed to attach to our receptors can’t
Once our natural hormone function is disrupted our bodies can’t regulate our systems efficiently.
How to avoid phthalates?
In order to limit your phthalate exposure, think fresh and limit your plastic usage.
Because many phthalates can be found in food packaging, going fresh at the grocery store can have a huge impact on your overall exposure.
- Buy fresh fruit and vegetables.
Though eating organic is useful in eliminating an array of phthalates it can also have a noticeable impact on your grocery budget. Non organic fruit and vegetables are okay too. If organic produce isn’t fiscally feasible, just make sure to give all your non organic fruit and vegetables a good water wash before cutting or biting into them.
If you decrease the processing (cutting, changing, repackaging etc.) of the food you buy you can actually decrease some phthalates. EXAMPLE: Buy a whole chicken vs. chicken tenders
- Store food in glass or paper containers.
Not only do glass containers tend to last longer and stand up to more washing than their plastic alternatives, they also take many phthalates out of the picture.
Buying a simple water filtration system can make a difference. While most tap water is considered safe to drink there may be trace elements of phthalates present that a simple water filter can remove.
- Keep plastic out of the microwave.
We understand that eliminating all plastic may not be possible but the process of microwaving a plastic container can actually release any phthalates it contains. This is how phthalates can get into your food.
- Choose your plastics wisely.
Plastics marked with any of the following recycling codes are potentially safe: PET, HDPE, LDPE and POLYPROPYLENE. We say “potentially” since current regulations do not require manufacturers to label their material. To be completely safe we recommend sticking to glass, paper, stainless steel, and wood alternatives.
If you would like more information on ways to deal with phthalates, please contact The Center for Internal and Integrative Medicine to schedule a consultation with Dr. Fatakhov.
ABOUT DR. FAT-OFF…
Eddie Fatakhov, M.D., a.k.a. Dr. Fat-off, is a Board-Certified Physician, Nutritionist, and Best-Selling Author of "The Doctors' Clinic-30 Program. His latest book is “Dr. Fat-Off Simple Life-Long Weight-Loss Solutions.”
Email: eddie@drfatakhov.com
Office: 404-836-9906
Website: www.eddiefatakhovmd.com
Facebook: https://www.facebook.com/fatakhov
Instagram: http://instagram.com/eddiefatakhovmd/
Premier Health Announces Binding LOI to Acquire Operating Pharmacy
- For the fiscal year 2017/18, the pharmacy has revenues of approximately $1MM and Adjusted EBITDA[1] of approximately 30%
- Advances Premier's long-term strategy of growing its business in each of the major verticals of primary care
VANCOUVER, Dec. 10, 2018 /CNW/ - Premier Health Group (CSE: PHGI) (OTCQB: PHGRF) (Frankfurt: 6PH) (the "Company" or "Premier Health"), a Company focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry, is pleased to announce that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent ("LOI") to acquire a Vancouver, British Columbia based pharmacy. The Company expects the acquisition to close in or about Q1-19.
"We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-based patient centric model," said Dr. Essam Hamza, CEO of Premier. "Premier has engaged with patients, pharmacies and technology providers to not only introduce pharmacy services as a component of our comprehensive telemedicine app, but also to explore and implement efficiencies in fill and fulfillment."
Under the terms of the LOI, the total consideration payable by Premier is $1,350,000, which will be paid as follows: (i) $200,000 deposit paid on signing of the LOI, (ii) $350,000 due on signing of a definitive agreement, (iii) $650,000 due on closing, (iii) $150,000 due six (6) months after closing.
The acquisition is subject to customary closing conditions, including execution of a definitive acquisition agreement and receipt of any required regulatory and stock exchange approvals.
The Company continues to evaluate additional pharmacy acquisitions and/or partnerships, which include bricks and mortar locations and strategic new retail opportunities. Additionally, the Company has engaged with healthcare technology providers and expects to provide further updates on its HealthVue app and other technology initiatives in the coming weeks.
Footnote:
- This news release contains references to Adjusted EBITDA from continuing operations, which is a non-IFRS metric. Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization, adjusted for non-recurring distributions to current owners. Premier uses EBITDA as it is a common measure used to assess profitability before the impact of different financing methods, income taxes, depreciation and impairment of capital assets and amortization of intangible assets. Premier believes that investors and financial analysts also use EBITDA to evaluate financial performance. EBITDA is not a measure of financial performance under IFRS and should not be considered as an alternative to operating income or any other measure of financial performance presented in accordance with IFRS. EBITDA excludes some, but not all, items that affect operating income.
ON BEHALF OF THE BOARD OF DIRECTORS
"Dr. Essam Hamza, MD"
Chief Executive Officer
About Premier Health
Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are developing innovative health care approaches that combine human skill based expertise with emerging technologies, with the goal of setting the gold standard for services in locations of interest worldwide. Premier Health's subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The HealthVue team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.
Cautionary Statements
This news release contains forward-looking statements that are based on Premier Health's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the acquisition of the pharmacy, including the timing thereof, and its plan to acquire additional pharmacies in the future. Although Premier Health believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Premier Health undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
This news release contains future-oriented financial information and financial outlook information (collectively, "FOFI") about Premier's prospective results of operations, including revenue and EBITDA, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. FOFI contained in this news release was made as of the date of this news release and was provided for the purpose of providing further information about Premier's future business operations. Premier disclaims any intention or obligation to update or revise any FOFI contained in this news release, whether as a result of new information, future events or otherwise, except as required by securities law. Investors are cautioned that the FOFI contained in this news release should not be used for purposes other than for which it is disclosed herein.
Non-GAAP Financial Measures
This news release contains non-generally accepted accounting principles ("GAAP") financial measures. The non-GAAP financial measures in this news release include EBITDA, or earnings before interest, taxes, depreciation and amortization. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Premier utilizes both GAAP and non-GAAP financial measures to assess what it believes to be its core operating performance and to evaluate and manage its internal business and assist in making financial operating decisions. Premier believes that the inclusion of non-GAAP financial measures, together with GAAP measures, provides investors with an alternative presentation useful to investors' understanding of Premier's core operating results and trends
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Premier Health Group Inc.
